Disease Domain | Count |
---|---|
Neoplasms | 5 |
Hemic and Lymphatic Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Proteolysis-targeting chimeras | 1 |
Chemical drugs | 1 |
Target |
Mechanism EIF2AK4 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HIF-PHs inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HSF1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CCT-251236 ( HSF1 ) | Neoplasms More | Preclinical |
IOX5 ( HIF-PHs ) | Acute Myeloid Leukemia More | Preclinical |
NXP-800 ( EIF2AK4 ) | Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma More | Preclinical |
CCT374705 ( BCL6 ) | Lymphoma More | Preclinical |
R1-ICR-5 ( RIPK1 ) | Neoplasms More | Discovery |